Profil
Nicholas Vlahakis worked as the Chief Medical Officer at CohBar, Inc. in 2022-2023.
Prior to that, he was the Vice President & Head of Clinical Development at Global Blood Therapeutics, Inc. and the Vice President & Head of Respiratory Disease at Unity Biotechnology, Inc. Mr. Vlahakis holds a doctorate degree from the University of Adelaide.
Anciens postes connus de Nicholas Vlahakis
| Sociétés | Poste | Fin |
|---|---|---|
| COHBAR, INC. | Directeur Technique/Scientifique/R&D | 01/05/2023 |
| UNITY BIOTECHNOLOGY, INC. | Corporate Officer/Principal | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Nicholas Vlahakis
| University of Adelaide | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| COHBAR, INC. | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
